Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 23, 2022 12:31pm
More details needed
Initiate Phase II bunionectomy trial – calendar H1 2023 this is the elephant in the room, until we get some information the stock is in a holding pattern. >how long will the trial be?
...more
(43)
•••
guilelesscat
X
View Profile
View Bullboard History
Comment by
guilelesscat
on Nov 22, 2022 2:30pm
RE:RE:RE:RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
For me, I'm all in at 150k shares. Dan either going bring me to an early retirement or grave.
(43)
•••
guilelesscat
X
View Profile
View Bullboard History
Comment by
guilelesscat
on Nov 22, 2022 12:31pm
RE:RE:RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
And assuming good P2-Bunionectomy results, the SP will jump up to at least $3. otherwise. The stock will crater, and we'll be sitting at below 20 cents. Place your bets.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 22, 2022 10:08am
RE:RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
Two definite angles at play here (IMO): 1. reduce the risk with OTENA and bring as much on the acute/chronic side to market over time. - this will add to our
...more
(218)
•••
baggerx99
X
View Profile
View Bullboard History
Comment by
baggerx99
on Nov 21, 2022 8:08pm
RE:RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
Lots of brain power working all aspects of piecing together a winning novel safe effective drug.Have the IP longevity extended to optimize reward for a partnering deal. Drug formulated for acute pain
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Nov 21, 2022 7:20pm
RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
I'd assume that's $1B USD for post-op in the USA alone - then you have Europe, Japan and LATAM to deal. Then we have other acute. Then working on an IV form for the futrure. Then you still
...more
(43)
•••
guilelesscat
X
View Profile
View Bullboard History
Comment by
guilelesscat
on Nov 21, 2022 6:48pm
RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
I mean it gave a lot more color. Now we know the bottleneck is with logistics, which should be cleared up in March. Yes, 1 billion for USA sales that is correct. All in all, it was a
...more
(2)
•••
Doccole
X
View Profile
View Bullboard History
Comment by
Doccole
on Nov 21, 2022 5:45pm
RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
He is difficult to listen to. ok, we will continue to be stuck here a long time. Heard lots of the same stuff. Did he say 1 billion for USA sales?
(37)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Nov 21, 2022 11:36am
Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
Webinar - Antibe Therapeutics $ATE w/ CEO Dan Legault Mon, November 21 at 4:15pm ET / 1:15pm PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar/register
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Nov 20, 2022 3:02pm
Tomorrow ...
Seeing these details for the first time ... "CEO Dan Legault will be providing a corporate update, including discussion of progress of it's lead drug otenaproxesul, targeting acute pain, as
...more
(174)
•••
Wriggles
X
View Profile
View Bullboard History
Comment by
Wriggles
on Nov 19, 2022 7:19pm
RE:Thanks for all your comments guys ...
Nanotech is only part of equation. The real thrust is the use of reactive compounds that scavenge or catylyze ROS. By attacking ROS you can treat the disease. H2S is a poor scavenger except
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Nov 19, 2022 6:54pm
Thanks for all your comments guys ...
So many unknowns but I do see some potential connections between our present and future drugs. Not sure where our use of nano fits - might be sooner than later or it might be well in the future - can&
...more
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Nov 19, 2022 4:36pm
RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
Given all the recent info on nanotechnology in oral pharmaceuticals I am not surprised he stepped down. i suspect the proof concept will expedite the process in general, and that we're on the
...more
(174)
•••
Wriggles
X
View Profile
View Bullboard History
Comment by
Wriggles
on Nov 19, 2022 3:32pm
RE:To do list ...
https://www.mdpi.com/2227-9059/10/1/85/htm Thanks for posting Mugsy. I wonder if ATE is thinking oxidative stress (OS). IBD is closely associated with OS. OS stems from excessive
...more
(81)
•••
Stutters
X
View Profile
View Bullboard History
Comment by
Stutters
on Nov 19, 2022 2:27pm
RE:RE:RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
lol... magicbox, you did bet money on it...and we are down to .48 cents from 6 bucks. Your bet has not paid off to say the least.
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >